LIXTE Biotechnology advances colon cancer treatment with Roche and Netherlands Cancer Institute
LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT and LIXTW), a trailblazer in clinical stage pharmaceutical development, has embarked on a groundbreaking clinical trial in partnership with Roche and the Netherlands Cancer Institute (NKI) to address immune therapy unresponsive metastatic colon cancer. This collaboration focuses on MSI Low metastatic colon cancer, which constitutes approximately 85% of colon […]